A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer

Prediction of Creatinine Clearance from Serum Creatinine

Donald W. Cockcroft, Henry Gault · ˜The œNephron journals/Nephron journals · 2008 · 15.4K citations

Pharmacy, Nephrology, Pharmacokinetics +15

Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases

W. Jeffrey Allard, Jeri Matera, Michael Craig Miller et al. · Clinical Cancer Research · 2004 · 2.5K citations

Medicine, Clinical Sciences, Oncology +14

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

A. Hilary Calvert, David R. Newell, Lindsey Gumbrell et al. · Journal of Clinical Oncology · 1989 · 1.9K citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

Kazumasa Noda, Yutaka Nishiwaki, Masaaki Kawahara et al. · New England Journal of Medicine · 2002 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +12

Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

Nasser H. Hanna, Paul A. Bunn, Corey J. Langer et al. · Journal of Clinical Oncology · 2006 · 678 citations · Full text

Medicine, Oncology, Pharmacology +10